CLRB
Cellectar Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.14
+0.00%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +41.1%
- EBIT
- +38.9%
- EPS
- +77.8%
- Free cash flow
- +43.8%
- Operating cash flow
- +43.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +4.2%
- EPS
- +50.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +51.2%
- EBIT
- +55.6%
- Net income
- +51.1%
- EPS
- +77.1%
- Free cash flow
- +51.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026